Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REPH

Recro Pharma (REPH) Stock Price, News & Analysis

Recro Pharma logo

About Recro Pharma Stock (NASDAQ:REPH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$1.47
$2.11
52-Week Range
N/A
Volume
141,800 shs
Average Volume
126,298 shs
Market Capitalization
$117.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Remove Ads
Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

REPH Stock News Headlines

Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
See More Headlines

REPH Stock Analysis - Frequently Asked Questions

Recro Pharma, Inc. (NASDAQ:REPH) released its quarterly earnings data on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative net margin of 15.15% and a negative trailing twelve-month return on equity of 56.66%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Gilead Sciences (GILD) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
3/01/2022
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REPH
Employees
185
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-11,370,000.00
Pretax Margin
-15.09%

Debt

Sales & Book Value

Annual Sales
$75.36 million
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
N/A

Miscellaneous

Free Float
48,412,000
Market Cap
$117.93 million
Optionable
Optionable
Beta
1.08
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:REPH) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners